STRATOS LV CRT-P AND STRATOS LV-T CRT-P, COROX OTW BP LEAD AND COROX OTW-S BP LEAD
Biotronik, Inc. · Decision date May 12, 2008
What did the FDA approve?
FDA approved the STRATOS LV CRT-P and STRATOS LV-T CRT-P with 702.U programmer software for the ICS 3000, along with the COROX OTW BP and COROX OTW-S BP leads. The pulse generators are indicated for patients with moderate to severe heart failure (NYHA Class III/IV), left ventricular dysfunction (EF < 35%), and QRS > 120 ms who remain symptomatic despite stable, optimal heart failure drug therapy.
The COROX OTW BP and COROX OTW-S BP are bipolar steroid-eluting left ventricular pacing leads intended for permanent implantation in the left ventricle via the coronary veins. They provide pacing and/or sensing when used with a compatible IS-1 pulse generator. The statement reports the approved indication and intended use; it does not independently establish safety or clinical effectiveness.
FDA approval order statement
APPROVAL FOR THE STRATOS LV CRT-P AND STRATOS LV-T CRT-P WITH 702.U PROGRAMMER SOFTWARE FOR THE ICS 3000 AND COROX OTW BP LEAD AND COROX OTW-S BP LEAD. THE STRATOS LV CRT-P AND THE STRATOS LV-T CRT-P ARE INDICATED FOR PATIENTS WHO HAVE MODERATE TO SEVERE HEART FAILURE (NYHA CLASS II1/IV), INCLUDING LEFT VENTRICULAR DYSFUNCTION (EF< 35%) AND QRS > 120 MS AND REMAIN SYMPTOMATIC DESPITE STABLE, OPTIMAL HEART FAILURE DRUG THERAPY. THE COROX OTW BP AND COROX OTW-S BP LEFT VENTRICULAR PACING LEADS ARE BIPOLAR STEROID-ELUTING LEADS, INTENDED FOR PERMANENT IMPLANTATION IN THE LEFT VENTRICLE VIA THE CORONARY VEINS TO PROVIDE PACING AND/OR SENSING WHEN USED IN CONJUNCTION WITH A COMPATIBLE IS-1 PULSE GENERATOR.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- May 12, 2008
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P070008
- Regulatory pathway
- Premarket approval application
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- Decision code
- APPR
- Decision date
- May 12, 2008
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Pulse generator, pacemaker, implantable, with cardiac resynchronization (CRT-P).
- Applicant
- Biotronik, Inc.
- Product code
- NKE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P070008 received
Application receipt date recorded by FDA.
P070008 · FDA decision
APPR
P070008/S179 · Related supplement
PSW 2601.U, NEO 2601.U
P070008/S172 · Related supplement
Edora 8 HF-T QP 407137 Edora 8 HF-T 407138 Evity 8 HF-T QP 407139 Evity 8 HF-T 407140 Enitra 8 HF-T QP 407141 Enitra 8 H
P070008/S182 · Related supplement
Edora 8 HF-T QP Edora 8 HF-T Evity 8 HF-T QP Evity 8 HF-T Enitra 8 HF-T QP Enitra 8 HF-T Enticos 8 HF-T QP Enticos 8 HF-
P070008/S181 · Related supplement
Edora 8 HF-T QP 407137; Edora 8 HF-T 407138; Evity 8 HF-T QP 407139; Evity 8 HF-T 407140; Enitra 8 HF-T QP 407141; Enitr
P070008/S183 · Related supplement
Edora 8 HF-T QP, Edora 8 HF-T, Evity 8 HF-T QP, Evity 8 HF-T, Enitra 8 HF-T QP, Enitra 8 HF-T
P070008/S177 · Related supplement
BIOexpress
P070008/S184 · Related supplement
Sentus ProMRI OTW QP S-75, Sentus ProMRI OTW QP S-85, Sentus ProMRI OTW QP S-95, Sentus ProMRI OTW QP L-75, Sentus ProMR
Timeline entries are records held by MedtechLedger for P070008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P070008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PSW 2601.U, NEO 2601.UP070008/S179 | Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 5, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP070008/S177 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code NKE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Guidant Corp. | PMA supplement | Oct 3, 2026 | FDA | |
| Guidant Corp. | PMA approval | Jan 26, 2004 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P070008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



